A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Trial Profile

A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use; Registrational
  • Acronyms FALCON
  • Sponsors Blue Earth Diagnostics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
    • 03 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top